T9549
Thrombin from bovine plasma
powder, suitable for cell culture, ≥1,500 NIH units/mg protein (E1%/280 = 19.5)
Synonym(s):
Factor IIa
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
form
powder
specific activity
≥1,500 NIH units/mg protein (E1%/280 = 19.5)
mol wt
heavy chain ~31 kDa
light chain ~6 kDa
technique(s)
cell culture | mammalian: suitable
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
Gene Information
cow ... F2(280685)
Looking for similar products? Visit Product Comparison Guide
General description
Thrombin is the final coagulation protease in regard to hemostasis, promoting both procoagulant and anticoagulant effects.
Application
Thrombin is used for site specific cleavage of recombinant fusion proteins containing an accessible thrombin recognition site for removal of affinity tags. Thrombin has been used in a study to assess an expression and purification system for the biosynthesis of adenosine receptor peptides for biophysical and structural characterization.
Biochem/physiol Actions
Serine protease that selectively cleaves Arg-Gly bonds in fibrinogen to form fibrin and fibrinopeptides A and B.
Unit Definition
Activity is expressed in NIH units, and is measured by direct comparison to an NIH thrombin reference standard.
Reconstitution
When reconstituted with 1 mL water, vial contains stated activity in 0.15 M sodium chloride and 0.05 M sodium citrate, pH 6.5.
Analysis Note
Activity is expressed in NIH units obtained by direct comparison to a NIH Thrombin Reference Standard, Lot K.
The NIH assay procedure uses 0.2 mL of diluted plasma (1:1 with saline) as a substrate and 0.1 mL of thrombin sample (stabilized in a 1% buffered albumin solution) based on a modification of the method of Biggs. Only clotting times in the range of 15-25 seconds are used for determining thrombin concentrations.
Other Notes
View more information on thrombin at www.sigma-aldrich.com/enzymeexplorer.
Inhibitor
Product No.
Description
Pricing
signalword
Danger
hcodes
Hazard Classifications
Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
Storage Class
11 - Combustible Solids
wgk_germany
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Zachary T Britton et al.
Protein expression and purification, 84(2), 224-235 (2012-06-23)
Biophysical and structural characterization of G protein-coupled receptors (GPCRs) has been limited due to difficulties in expression, purification, and vitro stability of the full-length receptors. "Divide and conquer" approaches aimed at the NMR characterization of peptides corresponding to specific regions
Andrew F Uehlin et al.
Pharmaceutics, 14(2) (2022-02-27)
In this study, we report a biohybrid oriented fibrous scaffold based on nanofibers of poly(l-lactic acid) (PLLA)/fibrin produced by electrospinning and subsequent post-treatment. Induced hydrolytic degradation of the fibers in 0.25 M NaOH solution for various time periods followed by
Yuya Nakatani et al.
Archives of oral biology, 73, 172-178 (2016-10-25)
Platelet-rich plasma (PRP) is typically isolated and applied immediately after preparation, making it both a time- and labor-intensive addition to the operative procedure. Thus, it would be convenient if PRP could be preserved. We evaluated the efficacy of freeze-dried PRP
Sharon Wei Ling Lee et al.
Advanced healthcare materials, 9(7), e1901486-e1901486 (2020-03-04)
Polymer nanoparticles (NPs), due to their small size and surface functionalization potential have demonstrated effective drug transport across the blood-brain-barrier (BBB). Currently, the lack of in vitro BBB models that closely recapitulate complex human brain microenvironments contributes to high failure
Walter-Michael Halbmayer et al.
Clinical chemistry and laboratory medicine, 50(9), 1601-1605 (2012-10-27)
Dabigatran etexilate is a new oral anticoagulant for the therapy and prophylaxis of venous thromboembolism and stroke prevention in patients with atrial fibrillation. To investigate the extent of interactions of this new anticoagulant with frequently used coagulation assays, we completed
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service